Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus VERSAPEN.
DYCILL vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic